Cannabis Is “An Effective Treatment” For Cancer Patients, Israeli Study Concludes

[Editor's note: This post is excerpted from this week's forthcoming NORML weekly media advisory. To have NORML's news alerts and legislative advisories delivered straight to your in-box, sign up here.]

Some two-thirds of Israeli cancer patients authorized to use cannabis report long-term, symptomatic improvement from the plant, according to clinical data presented in late January at a conference of the Israeli Oncologists Union and reported this week in several international media outlets.

Investigators at the Sheba Medical Center in Tel Aviv, in conjunction with the Israeli Cancer Association, assessed the efficacy of cannabis therapy over the course of one year in 264 patients with cancer. Israeli media reported the findings:

“Some 61 percent of the respondents reported a significant improvement in their quality of life as a result of the medical marijuana, while 56 percent noted an improvement in their ability to manage pain. In general, 67 percent were in favor of the treatment, while 65 percent said they would recommend it to other patients.”

The study concluded that cannabis is an “effective” treatment for certain symptoms of the disease cancer and recommended, “The treatment should be offered to the patients in earlier stages of cancer.”

In the trial, the most common types of cancer for which medical marijuana was authorized was lung cancer (21 percent ), breast cancer (12 percent ) and pancreatic cancer (10 percent ).

The study focused primarily on the use of cannabis to relieve various symptoms of cancer or cancer treatment, such as pain and nausea, but did not evaluate whether marijuana therapy could potentially suppress the proliferation of the disease. In preclinical trials, various cannabinoids – including THC and CBD (cannabidiol) – have been shown to selectively target and eliminate malignant cells and cancerous tumors.

To date, some 6,000 Israelis possess government authorization to use cannabis therapeutically. Patients authorized by the federal program may either cultivate cannabis at home or they may obtain marijuana from one of the nation’s 12 licensed cannabis farms.

Last summer, the Israeli Health Ministry formally acknowledged the therapeutic utility of cannabis and announced newly amended guidelines to more effectively govern the state-sponsored production and distribution of medical marijuana. The Ministry estimates that as many as 40,000 patients will eventually have access to medicinal cannabis once the Israeli program is fully implemented.

NORML’s literature review of the anti-cancer properties of cannabis and cannabinoids is available here.

This Week in Weed: August 7th – 13th

NORMLtv is pleased to announce the newest addition to its programming lineup, “This Week in Weed.” This new weekly video series covers the most newsworthy stories shaping the marijuana law reform world. Our first installment covers Israel’s growing acceptance of medical cannabis, which states in the US have the highest use rates, and new polling on support for legalization.

Be sure to tune in to NORMLtv each Thursday afternoon to catch up on the latest marijuana news. Subscribe to NORMLtv or follow us on Twitter to get notified as soon as new content is added.

Don’t miss out on our previous content including a new PSA, Willie Nelson supporting HR 2306, and coverage from DC’s Drug War Victims Vigil.

Israeli Government Officially Recognizes The Therapeutic Value Of Cannabis — Pot Production And Distribution To Begin January 2012

[Editor's note: This post is excerpted from this week's forthcoming NORML weekly media advisory. To have NORML's media alerts and legislative advisories delivered straight to your in-box, sign up here. You can also view a video version of this and other stories here on NORML's new youtube feature: "This Week in Weed."]

The Israeli government this week formally acknowledged the therapeutic utility of cannabis and announced newly amended guidelines governing the state-sponsored production and distribution of medical cannabis to Israeli patients.

A prepared statement posted Monday on the website of office of the Israeli Prime Minister states: “The Cabinet today approved arrangements and supervision regarding the supply of cannabis for medical and research uses. This is in recognition that the medical use of cannabis is necessary in certain cases. The Health Ministry will – in coordination with the Israel Police and the Israel Anti-Drug Authority – oversee the foregoing and will also be responsible for supplies from imports and local cultivation.”

According to Israeli news reports, approximately 6,000 Israeli patients are supplied with locally grown cannabis as part of a limited government program. This week’s announcement indicates that government officials intend to expand the program to more patients and centralize the drug’s cultivation. “[T]here are predictions that doctor and patient satisfaction is so high that the number could reach 40,000 in 2016,” The Jerusalem Post reported.

The Israeli Ministry of Health is expected to oversee the production of marijuana in January 2012.

Similar government-sponsored medical marijuana programs are also active in Canada and the Netherlands.

By contrast, in July the United States Drug Enforcement Administration (DEA) formally denied a nine-year-old petition calling on the agency to initiate hearings to reassess the present classification of marijuana as a schedule I controlled substance, stating in the July 8, 2011 edition of the Federal Register that cannabis has “a high potential for abuse; … no currently accepted medical use in treatment in the United States; … [and] lacks accepted safety for use under medical supervision.”

Can This Man Ever Tell The Truth?

What do you know?  Drug Czar John Walters has been outed as a liar — again. I mean, seriously, let’s hope this guy is more honest when he’s filing his taxes than he is when he’s talking about pot. 

The Czar’s latest reefer faux pas? According to a previous, widely distributed ONDCP press release: “Marijuana affects … many of the skills required for safe driving. … These effects can last up to 24 hours after smoking marijuana.” 

Twenty-four hours, huh?  Well, an Israeli investigative team recently tested Walters’ claim — giving subjects high and low doses of THC and then measuring their driving performance.  Their conclusion, “No THC effects were observed after 24 hours on any of the measures.” 

This finding is not to say that concerns regarding motorists — especially teens — driving after smoking marijuana are not without merit. For example, the study’s authors found that pot, even at low doses, impaired drivers’ ability to maintain lane position and significantly increased subjects’ reaction time.

Intriguingly, however, the investigators reported that marijuana’s most prominent impact on driving differed dramatically from that of alcohol.

“Average speed was the most sensitive driving performance variable affected by both THC and alcohol but with an opposite effect,” authors concluded. “In particular, subjects seemed to be aware of their impairment after THC intake and tried to compensate by driving slower; alcohol seemed to make them overly confident and caused them to drive faster than in control sessions.”

To hear my expanded thoughts on this study, check out NORML’s 5/19/08 podcast here, or download a copy of NORML’s report, “Cannabis and Driving: A Scientific and Rational Review,” available here.